Squarepoint’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Squarepoint’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-23,877	Closed	-$88K	–	2454
2017 Q4	$88K	Buy	+23,877	New	+$97.8K	﹤0.01%	1973
2017 Q2	–	Sell	-37,650	Closed	-$156K	–	1997
2017 Q1	$156K	Buy	+37,650	New	+$158K	﹤0.01%	1341
2016 Q3	–	Sell	-18,533	Closed	-$105K	–	1414
2016 Q2	$105K	Buy	+18,533	New	+$126K	0.01%	973
2016 Q1	–	Sell	-4,850	Closed	-$65K	–	1609
2015 Q4	$65K	Buy	+4,850	New	+$83.5K	0.01%	1173

Squarepoint's CASC Position: Q1 2018 in Review

Squarepoint sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 23,877 shares — an estimated $88K sold.

Squarepoint first reported a position in CASC in Q4 2015 and held it in 4 quarters. The position peaked at $156K in Q1 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Squarepoint reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Squarepoint sold 23,877 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $88K.
Squarepoint first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and held it in 4 quarters.
Squarepoint's Cascadian Therapeutics, Inc. position peaked at $156K in Q1 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Squarepoint's 13F filing for Q1 2018, filed 15 May 2018.